Publications
Aug 20, 2025
External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands
See More
Aug 20, 2025
External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands
See More
Press Releases
Jun 18, 2025
PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
See More
Jun 18, 2025
PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
See More
Posters & Abstracts
Dec 9, 2024
San Antonio Breast Symposium-24: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype
See More
Dec 9, 2024
San Antonio Breast Symposium-24: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype
See More
Press Releases
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Press Releases
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Media Coverage
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Press Releases
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Publications
Jul 9, 2024
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
See More
Jul 9, 2024
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
See More
Posters & Abstracts
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Press Releases
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
No results.
Contact us today to learn more about PreciseBreast.
